Moreover, the study showed a trend of longer duration of additional OFS to TMX for patients with higher clinical and genomic risks and without adjuvant chemotherapy.
← all excerpts
Survey of clinicians on the use of adjuvant therapy for premenopausal women with breast cancer.
1
—
—